Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Ocular Therapeutix Inc shares valued at $277,790 were sold by Saroj Namrata on Nov 05 ’25. At $10.74 per share, Saroj Namrata sold 25,865 shares. The insider’s holdings dropped to 174,135 shares worth approximately $1.95 million following the completion of this transaction.
Also, NAMRATA SAROJ purchased 25,865 shares, netting a total of over 277,909 in proceeds.
Before that, Anderman Todd had sold 11,132 shares from its account. In a trade valued at $137,369, the Chief Legal Officer traded Ocular Therapeutix Inc shares for $12.34 each. Upon closing the transaction, the insider’s holdings decreased to 11,132 shares, worth approximately $0.98 million.
As published in their initiating research note from Chardan Capital Markets on September 15, 2025, Ocular Therapeutix Inc [OCUL] has been a Buy and the price target has been revised to $21. Analysts at William Blair started covering the stock with ‘”an Outperform”‘ outlook in a report released in early April. As of March 18, 2025, RBC Capital Mkts has initiated its “an Outperform” rating for OCUL. Earlier on March 11, 2025, Needham initiated its rating. Their recommendation was “a Buy” for OCUL stock.
Analyzing OCUL Stock Performance
On last trading session, Ocular Therapeutix Inc [NASDAQ: OCUL] plunged -2.61% to $11.19. The stock’s lowest price that day was $11.18, but it reached a high of $11.6 in the same session. During the last five days, there has been a surge of approximately 5.27%. Over the course of the year, Ocular Therapeutix Inc shares have jumped approximately 2.10%. Shares of the company reached a 52-week high of $13.85 on 09/05/25 and a 52-week low of $5.78 on 03/04/25.
Support And Resistance Levels for Ocular Therapeutix Inc (OCUL)
According to the 24-hour chart, there is a support level at 11.05, which, if violated, would cause prices to drop to 10.90. In the upper region, resistance lies at 11.47. The next price resistance is at 11.74. RSI (Relative Strength Index) is 46.50 on the 14-day chart, showing neutral technical sentiment.
Is Ocular Therapeutix Inc subject to short interest?
Stocks of Ocular Therapeutix Inc saw a sharp rise in short interest on 2025-10-31 jumping by 0.22 million shares to 13.77 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 13.56 million shares. A jump of 1.57% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 4.0 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.0.
Which companies own the most shares of Ocular Therapeutix Inc (OCUL)?
In terms of Ocular Therapeutix Inc share price expectations, FactSet research, analysts set an average price target of 26.5 in the next 12 months, up nearly 130.64% from the previous closing price of $11.49. Analysts anticipate Ocular Therapeutix Inc stock to reach 31 by 2025, with the lowest price target being 19. In spite of this, 3 analysts ranked Ocular Therapeutix Inc stock as Buy at the end of 2025.
